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Abstract: Mild parkinsonian signs (MPS) may be found among patients presenting with mild 
cognitive impairment (MCI), but few data are available about the relation of these signs with the 
prospective risk for dementia. Our retrospective investigation considered a case-series of 119 
MCI subjects followed over a three-year period: their baseline clinical picture has been analyzed 
in search of correlation between the cognito-motor proﬁ le and the ﬁ nal diagnosis. The population 
included 66 patients with amnesic MCI and 53 with an involvement of other cognitive areas 
(nonamnesic MCI). MPS were detected in 22 subjects (18.5%). At the ﬁ rst observation, MPS 
cases showed an higher frequency of nonamnesic MCI and more pronounced deﬁ cits at the Trail 
Making Test (p  0.05). After a three-year follow-up, 48 patients had converted to dementia. 
The presence of MPS at the baseline evaluation was signiﬁ cantly related to the development 
of a vascular-type dementia. The study investigates the association between MPS and MCI and 
might indicate for these cases a greater risk for an involvement of executive functions and the 
subsequent development of vascular dementia.
Keywords: mild cognitive impairment, dementia, cerebrovascular disease, parkinsonism
Introduction
Parkinsonian signs such as gait disturbances, rigidity, bradykinesia and tremor are com-
mon among older adults and signiﬁ cantly associated with negative outcomes such as 
dementia and death (Wilson et al 2002; Louis et al 2004). A recent study shows that 
mild parkinsonian signs (MPS), especially rigidity, may frequently be observed among 
patients with amnestic mild cognitive impairment (MCI) and that these two conditions may 
share a common pathogenesis (Louis et al 2005). In an another study, subjects with MCI 
showed associated parkinsonian signs more frequently than controls without cognitive 
impairment. Among patients with MCI, lower levels of cognitive functioning, particularly 
in perceptual speed, were also associated with higher levels of parkinsonism (Boyle et al 
2005). In contrast to previous ﬁ nding of a unique association between amnestic MCI and 
parkinsonism, the study by Boyle and colleagues (2005) suggests that parkinsonian signs 
may be more prominent among individuals with nonamnestic forms of MCI (ie, with 
involvement of multiple areas). Moreover the association between MCI and parkinsonism 
is not completely explained by vascular risk factors or vascular disease.
A longitudinal cohort study involving older Catholic clergy membership 
concluded that persons with MCI also have impaired motor function, and the degree 
of impairment in lower extremity function is related to risk of Alzheimer’s disease 
(Aggarwal et al 2006).
The basis for these signs is unclear, but is likely to be multifactorial, including an 
age-associated decline in dopaminergic nigrostriatal activity, the early development 
of neurodegenetative (Lewy body or Alzheimer’s diseases) pathologies in the basal 
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ganglia, or the accumulations of vascular pathology in the 
brain (Louis and Bennet 2007). Recent neuropathological 
studies indicate that neuronal loss in substantia nigra, partly 
related to tau lesions, is a major pathological substrate of 
extrapyramidal signs (EPS) in Alzheimer’s disease (AD). 
EPS in elderly patients may be a surrogate marker for severe 
neuritic AD pathology (Attems et al 2007).
On the other hand, impairment of cognitive function 
has been demonstrated even in newly diagnosed Parkinson 
disease patients (PD), with deﬁ cits being most prominent in 
the domains of memory and executive functions; also, an older 
age at disease onset is likely to be an important determinant 
of cognitive dysfunction in PD (Muslimovic et al 2005).
Based on these reports, we have tried to investigate how 
the association between MCI and MPS may be related to 
the evolution towards different type of dementias or other 
neurodegenerative disorders.
Methods
In this retrospective investigation we considered a case-
series of subjects ﬁ tting the criteria for MCI (Petersen et al 
2001), folllowed over a three-year period. During this time, a 
population of 135 consecutive cases was observed but, at the 
present moment, 16 subjects were lost at follow-up (7 died 
and 9 were not evaluated for poor compliance). The analysis 
was conducted on 119 cases (73.1 ± 5.7 years, M/F 50/69). 
The participants involved in this study were recruited from 
outpatients attending the Laboratory of Neuropsychology 
and the Alzheimer’s Unit (UVA) at the Ospedale di Circolo 
and Fondazione Macchi in Varese, Italy.
After the ﬁ rst examination, MCI subjects were evaluated 
every 12 months to detect the patients who converted to 
dementia. We considered the baseline clinical picture in search 
of correlation between cognito-motor proﬁ le and the ﬁ nal 
diagnosis of dementia, as deﬁ ned by the current clinical criteria 
(McKhan et al 1984; Morris 1993; The Lund and Manchester 
Groups 1994; Erkinjuntti et al 2000; McKeith et al 2005).
All cases underwent, at the baseline examination, a 
standard neurological examination, laboratory tests (routine 
blood samples, thyroid, B12 and folate, Venereal Disease 
Research Laboratory), neuroimaging investigation (brain 
computed tomography [CT]) in order to exclude secondary 
causes of brain organic dysfunction. The use of psychiatric 
drugs that may affect cognition or motor functions (such as 
antipsychotics or anticholinergic) was also excluded.
A validated CT-based weighted rating scale sensitive 
to detect different degrees of subcortical ischemic vascular 
disease (SIVD) was also calculated. This rating scale is valid 
and is sensitive to capture different degrees of SIVD associated 
with mild cognitive deterioration (Geroldi et al 2003).
Neurological examination included the motor portion of 
the Uniﬁ ed Parkinson Disease Rating Scale (UPDRS). MPS 
was determined by the presence of changes in axial function, 
rigidity or tremor (Louis et al 2004).
All the patients underwent a standardized neuropsycho-
logical battery, designed to assess cognitive functions that 
are generally involved in dementia: orientation, memory, 
attention, information processing speed, abstract reasoning, 
language and visuospatial ability. Tests administered included: 
Clinical Dementia Rating scale (CDR) (Morris 1993) for 
staging of dementia, Mini Mental State Examination (MMSE) 
(Folstein et al 1975), Trail Making Test part A and B (TMT) 
(Giovagnoli et al 1996), and Mental Deterioration Battery 
(MDB) (Carlesimo et al 1996). The MDB is comprised of eight 
tests, four are expressions from the processing of verbal mate-
rial and four derive from the processing of visuospatial material. 
The verbal tests are: immediate (IR) and delayed recall (DR) of 
Rey’s 15 words, word ﬂ uency (FAS), and phrase construction. 
The visuospatial tests are: Raven’s 47 progressive colored 
matrices, immediate visual memory (IVM), and copying of 
drawings freehand (CD FH) and with landmarks (CD WL).
Affective symptoms were assessed using the Geriatric 
Depression Scale (GDS) (Yesavage et al 1983). GDS scores 
were used to exclude patients with severe depression and as 
control variable between the different groups. Instrumental 
activities of daily living (IADL) were also investigated 
(Lawton and Brody 1969).
Statistical analysis
Standardized and validated Italian language versions of all 
the tests are available. The cognitive performances of the 
patients were evaluated against normative data for the Italian 
population. Raw scores from each test were corrected for age, 
sex, and education and transformed into corrected scores, in 
accordance with Italian standardization studies.
A logistic regression analyses were performed using MPS 
status and type of dementia as the dependent variables and 
all the other relevant variables as predictors (SPSS version 
13.0, SPSS Inc., Chicago, IL, USA).
Results
Baseline evaluation
Our population (119 cases of MCI) included, in according 
with the results of the baseline neuropsychological battery, 
66 (55.5%) subjects with selective memory impairment 
(amnesic MCI) and 53 (45.5%) with an involvement of other 
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cognitive areas (nonamnesic MCI). Among nonamnesic 
MCI the cognitive proﬁ le was characterized by a selective 
impairment of executive function or by a diffuse borderline 
performance.
According to Petersen criteria, MMSE scores, corrected 
by age and education, were within the normal range. At the 
time of the ﬁ rst examination study participants obtained a 
score equal to 0.5 (questionable dementia) at the CDR scale 
for staging of dementia, without signiﬁ cant impairment in 
social functioning (IADL).
MPS were detected in 22 subjects (18.5%) with postural 
instability and gait difﬁ culty in 16 patients and dominant 
tremor in 6 cases. The presence of MPS were more frequent 
(p  0.05) among nonamnesic MCI (13/53) in respect to 
amnesic MCI (9/66). Demographic variables and cognitive 
performances among patients with (MPS+) and without MPS 
(MPS-) are reported in Table 1. At the baseline observation 
the analyses of cognitive proﬁ le showed a worse performance 
of the TMT (B-A) in the MPS+ group (p  0.05), without 
signiﬁ cant differences for the other cognitive, affective and 
functional variables.
No signiﬁ cant difference was detected for GDS score 
between the two groups.
Furthermore in these cases the evaluation of basal brain 
CT scan pointed out the presence of a greater presence of 
moderate to severe subcortical vascular abnormalities – SIVD 
(Figure 1) that, however, did not reached the statistical sig-
niﬁ cance. The analysis of comorbility revealed an higher 
presence of vascular risk factors for nonamnesic group with a 
signiﬁ cant difference (p  0.05) for previous TIA or lacunar 
syndromes. These events had occurred before the onset of 
cognitive complaints thus excluding a direct cause–effect 
relationship.
Follow-up
After a three-year follow-up 48/119 MCI patients (40.5%) 
had converted to possible or probable dementia of different 
types: Alzheimer’s disease (AD), 31 (64.5%); Lewy Body 
dementia (LBD), 7 (14.5%); vascular dementia, 8 (16.5%); 
or fronto-temporal dementia (FTD), 2 (4.5%). Two cases of 
MPS group did not develop a progression towards dementia 
but were diagnosed as idiopathic PD. The classiﬁ cation of 
different type of dementia was made on the basis of the criteria 
exposed in the material and methods. Brain CT or magnetic 
resonance imaging (MRI) scans were repeated when neces-
sary to conﬁ rm the clinical features of vascular dementia.
The annual rate of conversion to dementia of the entire 
population is reported in Figure 2: the group with MPS showed 
a more evident trend to the development of dementia.
MPS was present, at the baseline evaluation in 4/31 cases 
of AD, 2/7 of LBD, and 5/8 of vascular dementia. On this 
basis, the presence of MPS was signiﬁ cantly related to 
Table 1 Demographic and clinical variables of patients with (MPS+) 
and without MPS (MPS−)
Demographic variables MPS+ (N, 22) MPS− (N, 97)
Age 74 ± 6.1 72.8 ± 5.3
Sex m/f 12/10 41/56
Education 6.9 ± 3.1 7.1 ± 3.4
Dementia variables
GDS 10.2 ± 5.1 8.7 ± 4.4
IADL 7.4 ± 0.6 7.6 ± 0.4
MMSE 26.9 ± 1.6 27.2 ± 1.8
Comorbility
Hypertension 11 (50) 31 (32)
Diabetes 2 (9) 5 (5)
TIA/minor stroke° 4* (18) 3 (3)
Ischemic cardiopathy 4 (18) 14 (14.5)
Notes: *p  0.05 Chi-square test; °Events occurred before the onset of cognitive 
complaints thus excluding a direct cause-effect relationship.
Abbreviations: GDS, geriatric depression scale; IADL, instrumental activity of daily 
living; MMSE, mini mental state examination.
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Figure 1 Distribution of computed tomography (CT)-based weighted rating scale 
for subcortical ischemic vascular disease (percentage of cases) among subjects with 
and without MPS.
Baseline CT score for SIVD: O absent; 1 mild, 2 moderate, 3 severe degree 
of subcortical ischemic vascular disease.
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Figure 2 Cumulative rate of conversion to dementia over a three-year follow-up.
Notes: MCI: all cases observed (N, 119), MPS+ patient with mild parkinsonian signs 
(N, 22), MPS− patients without mild parkinsonian signs (N, 97).
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the development of vascular dementia (p  0.05). On the 
other hand patients with vascular dementia showed, at the 
baseline brain CT scan, moderate to severe SIVD, whereas 
SIVD alterations were similar among AD and LBD groups. 
Neuropsychological performance of the vascular dementia 
group was characterized by worse scores at TMT at the 
baseline examination, which did not reached a signiﬁ cant 
value probably due to the very low number of cases.
No signiﬁ cant difference in the occurrence of MPS was 
detectable at the ﬁ rst evaluation between patients converted 
to AD and LDB, the cognitive proﬁ le revealed only a worse 
performance in the copy of drawings among the LDB 
group.
Discussion
Mild cognitive impairment represents a condition charac-
terized by different neuropsychological proﬁ le (amnesic, 
nonamnesic, multiple areas defects). During the last years 
several clinical and noncognitive aspects were also inves-
tigated such as comorbidity, the prevalence of psychiatric 
syndromes and symptoms (Apostolova and Cummings 
2008) and, recently, the medical decision making-capacity 
of these subject (Okonkwo et al 2007). The present study 
focused the attention on the presence of MPS in a group 
of amnesic and nonamnesic MCI followed for a three-year 
period. Our data conﬁ rm the relevance of the association 
between MPS and MCI and might indicate an higher chance 
for these cases to develop dementing conditions related to 
vascular disease.
In the study by Louis and colleagues (2004), MPS, 
especially rigidity, are associated with amnestic MCI. Moreover 
the authors suggested that MPS and MCI may share similar 
pathogenesis. The observation that MPS were associated with 
vascular risk factors and vascular disease suggests that cerebro-
vascular disease may contribute to both conditions.
In contrast to this ﬁ nding of a unique association between 
amnestic MCI and MPS, the results of Boyle and colleagues 
(2005) suggested that MPS may be more prominent among 
individuals with non-amnestic MCI as opposed to amnestic 
MCI. Another study demonstrated that the severity of MPS 
was related to the severity of cognitive impairment, in 
particular nonmemory functions, and also to a different pattern 
of psycho-behavioral symptoms (Rozzini et al 2007).
In our study, MPS occurred in 22 out of 119 cases 
(18.5%) that differed from the rest of population for a 
greater impairment of executive function and, subsequently, 
a greater number of cases with nonamnesic MCI. In 
particular a pathological or borderline score at the TMT 
signiﬁ cantly divided the two groups with and without MPS. 
This association, as observed by Boyle and colleagues, 
could indicate that the involvement of executive functions 
is consistent with the dysfunction of fronto-subcortical sys-
tems and the development of parkinsonian signs (Wilson 
et al 2002).
Among MPS patients the analysis of movement disorders 
showed a prevalent presence of postural instability and gait 
disturbances (PIGD). With regard to this ﬁ nding a recent 
study conﬁ rmed that PIGD motor subtype was associated 
with a faster rate of cognitive decline in PD and may be 
considered a risk factor for incident dementia in PD (Burn 
et al 2006).
Over a three-year period, 48 MCI cases converted to 
dementia and the presence of MPS signs, at the baseline 
evaluation, is signiﬁ cantly related to the development of 
SIVD. Among these two groups, the presence of vascular 
abnormalities was, as expected, showed more evidence for 
vascular dementia. No difference between AD and LBD 
was detected.
A recent study on a large group of MCI patients conﬁ rmed 
that, in the context of pervasive episodic memory impairment, 
tests assessing the free recall of verbal material following 
a delay interval demonstrated the greater sensitivity to 
memory deﬁ cits of amnesic MCI subjects who developed 
AD (Perri et al 2007). On the contrary, strategic cerebrovas-
cular lesions detected by MRI in patients with CDR score 
equivalent to 0.5 were associated with impaired TMT B 
performances. In particular executive dysfunction was prob-
ably based on an impaired fronto-subcortical circuit (Ishii 
et al 2007). In some vascular dementia subtypes, particularly 
those caused by subcortical microvascular disease, dementia 
may be preceded by MCI, which has similar domains of 
cognitive impairment and similar progressive course that 
may mimic AD (Meyer et al 1981).
Although a MRI examination was available only for 
few cases and a CT weighted scale was used, these ﬁ ndings 
also indicated that MCI with MPS is partly explained by the 
occurrence of vascular ischemic abnormalities.
Moreover during the follow-up period we observed 
several cases converted to different types of dementia 
including LBD, but 2 patients also developed a PD associated 
with MCI. Two different studies showed that, in newly 
diagnosed PD, a cognitive dysfunction ranging from 24% to 
36% was detectable (Foltynie et al 2004; Louis et al 2005). 
This ﬁ nding could indicate that cognitive dysfunctions in 
early PD may reﬂ ects neuropathological changes that are 
distinct from those associated with motor disorders.
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The overlap between these different conditions suggests 
that the mechanisms underlying MPS are probably 
heterogeneous with a range of potential pathophysiological 
processes that include nerodegenerative and vascular 
pathologies (Louis and Bennet 2007).
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